Compare AMCX & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCX | THW |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Finance Companies |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.0M | 565.9M |
| IPO Year | 2011 | 2015 |
| Metric | AMCX | THW |
|---|---|---|
| Price | $10.93 | $12.05 |
| Analyst Decision | Sell | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 553.5K | 104.4K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | N/A |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.47 | $11.18 |
| 52 Week High | $12.93 | $14.50 |
| Indicator | AMCX | THW |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 23.65 |
| Support Level | $9.23 | $12.04 |
| Resistance Level | $11.13 | $12.92 |
| Average True Range (ATR) | 0.40 | 0.33 |
| MACD | -0.14 | -0.13 |
| Stochastic Oscillator | 14.16 | 8.18 |
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.